Summary
RenaissThera, a Bengaluru-based company founded in 2023, is developing oral small-molecule drugs for obesity and type 2 diabetes, focusing on targets like GLP-1 and GIP. The company has raised seed funding and is using AI and machine learning in its drug discovery process, with seven programs currently at the discovery stage.